KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) R&D In Process (2021 - 2025)

Regeneron Pharmaceuticals (REGN) has 4 years of R&D In Process data on record, last reported at $18.7 million in Q4 2025.

  • For Q4 2025, R&D In Process rose 35.51% year-over-year to $18.7 million; the TTM value through Dec 2025 reached $124.1 million, up 22.87%, while the annual FY2025 figure was $124.1 million, 22.87% up from the prior year.
  • R&D In Process reached $18.7 million in Q4 2025 per REGN's latest filing, down from $83.1 million in the prior quarter.
  • Across five years, R&D In Process topped out at $255.1 million in Q4 2022 and bottomed at $7.1 million in Q1 2024.
  • Average R&D In Process over 4 years is $63.7 million, with a median of $29.0 million recorded in 2022.
  • The widest YoY moves for R&D In Process: up 99.64% in 2023, down 88.24% in 2023.
  • A 4-year view of R&D In Process shows it stood at $255.1 million in 2022, then crashed by 88.24% to $30.0 million in 2023, then crashed by 54.0% to $13.8 million in 2024, then skyrocketed by 35.51% to $18.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for R&D In Process were $18.7 million in Q4 2025, $83.1 million in Q3 2025, and $10.0 million in Q2 2025.